MENU
JPMA
  • Access
  • Japanese
  • About JPMA

    About JPMA Top

    • Message from the President
    • Outline of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • About Pharmaceuticals

    About Pharmaceuticals Top

    • General Drug Guide
    • Clinical Trials Information
    • Together with Patients
  • Information from the Committee

    Information from the Committee Top

    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R&D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • Newsletter
  • News Room

    Newsroom Top

    • News Release
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA's video content and advertisements
  • The Office of Pharmaceutical Industry Research
Close
JPMA

Return to Site Top

  • For Patients and the Public (About Pharmaceuticals)
    For Patients and the Public (Pharmaceuticals) Top
    • General Drug Guide
    • Clinical Trials Information
    • Together with Patients
  • Information from the Committee
    Information from the Committee Top
    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R&D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • About JPMA
    About JPMA Top
    • Message from the President
    • Outline of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • Policies and Activities
    Policies and Activities Top
    • Business Policy, Business Plan, and Implementation Plan
    • Committee Activities
    • Convention on Biological Diversity
  • Voluntary Standards
    Voluntary Standards Top
    • Charter of Conduct
    • JPMA Code of Practice
    • Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
    • Transparency Guideline for Relationships between Corporate Activities and Patient Groups
    • Guidelines for the Preparation of Product Information Summaries for Ethical Drugs (Abbreviated name: Preparation Guidelines)
    • Clinical Research
    • Basic Philosophy and Action Guidelines on Biodiversity
    • Guidelines Concerning Appropriate Competition in Japan Pharmaceutical Manufacturers Association Meetings
    • Guidelines for the Promotion of Pharmaceutical Industry in Japan
  • News Room
    Newsroom Top
    • News Release
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA's video content and advertisements
  • The Office of Pharmaceutical Industry Research  Page will open in a new window.
  • Social Media Policy
  • Website Terms of Use
  • Vision, Policy Proposals
    Vision, Policy Proposals Top
    • Toward Realizing the JPMA's Vision for 2035
    • Chairman's Press Conference, Speeches and Comments
    • Back Number: Vision, Proposals
  • Access
  • Japanese
  • Top
  • Information from the Committee
  • Drug Evaluation Committee
  • Drug Evaluation Committee Symposium
  • Materials for "Workshop for Practitioners on Electronic Data Submission at the Time of Application" in FY2022

Drug Evaluation Committee Materials for "Workshop for Practitioners on Electronic Data Submission at the Time of Application" in FY2022

Mar 02, 2023

  • 00_Program (170KB)
  • 01_Examination of the relationship between explanatory materials (Form A) and data guides for electronic data at the time of application (1.84MB)
  • 02. Proposal of Best Practice for electronic data submission using data prepared by other companies (3.94MB)
  • 03_Electronic Data Submission for PPK Analysis: What You Need to Know (3.84MB)
  • 04_Questionnaire results on the impact of eCTD v4.0 on the electronic data submission process (886KB)
  • 05. Points that CDISC staff of CROs should pay attention to when complying with eCTD V4.0 (862KB)
  • 06_Current Status and Points to Consider Concerning Electronic Data Submission of Applications (840KB)
  • 07_Update on eCTD v4 and Gateway (1.96MB)
  • 08_Introduction of internal process study for electronic data submission of applications with eCTD Ver. 4.0 (1.31MB)
  • 09_Best Practices for Early Transition to Online Submission as Communicated by Regulatory Affairs Operations Involved in Gateway Submission from the Early Days (1.38MB)

Return to Drug Evaluation Committee Symposium Top

Share this page

  • Tweet
  • Share this page

TOP

Site Search

  • Top
  • Information from the Committee
  • Drug Evaluation Committee
  • Drug Evaluation Committee Symposium
  • Materials for "Workshop for Practitioners on Electronic Data Submission at the Time of Application" in FY2022
  • JPMA PR and Communication Activities
  • Pharmaceutical Research Institute
  • List of Non-Financial Information Disclosure by Member Companies
  • STOP AMR
  • About JPMA
  • Policies and Activities
  • Voluntary Standards
  • Global Health
  • News Room
  • For Patients and the Public (About Pharmaceuticals)
  • Clinical Trials Information
  • Information from the Committee
  • JapanesePage will open in a new window.
  • x
  •  facebook
  •  youtube
  • Site Map
  • Website Terms of Use
  • Privacy Policy
  • Social Media Policy
  • Linking Policy
  • Accessibility Policy
  • PRAISE-NET Login

© Japan Pharmaceutical Manufacturers
Association(JPMA).

Notification

This website uses automatic translation.
The translated content may not always be fully consistent with the original Japanese content.